Samsung Bioepis Co., Ltd.
http://www.samsungbioepis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Samsung Bioepis Co., Ltd.
The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
Samsung Bioepis Reveals Ustekinumab Progress
Samsung Bioepis has reported positive Phase I data for its SB17 ustekinumab candidate, a proposed biosimilar to Stelara.
Biogen Launches Lucentis Biosimilar Byooviz In Canada
Biogen has launched the Samsung Bioepis-developed Byooviz version of Lucentis in Canada, marking the first and only ranibizumab biosimilar to be approved and introduced in the market.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Samsung Biologics
- Samsung Bioepis JV
- Samsung Bioepis BR Pharmaceutical LTDA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice